RFL
Real EstateRafael Holdings, Inc.
$1.27
+$0.01 (+0.79%)
Jan 5, 2026
Price History (1Y)
Analysis
Rafael Holdings, Inc. is a publicly traded company with a market cap of $65.74 million and operates in the Real Estate sector, specifically within the Real Estate Services industry. The company has a relatively small scale, employing 21 individuals. Financially, Rafael Holdings has experienced significant net losses, with a Net Income (TTM) of -$31,330,000. The company's profitability is indicated by margins: Gross Margin at 89.7%, Operating Margin at -4225.4%, and Profit Margin at 0.0%. Returns on equity and assets are also negative, with Return on Equity at -37.5% and Return on Assets at -20.4%. The balance sheet shows a relatively low debt level of $664,000 against a substantial cash reserve of $45.54 million. The company's valuation metrics indicate a Price to Book ratio of 0.77 and a Price to Sales ratio of 63.89. Revenue growth has been significant at 87.5% year-over-year, but Earnings Growth is not available. The Current Ratio is 4.00, suggesting the company has sufficient liquidity to cover its short-term obligations.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Rafael Holdings, Inc.
Rafael Holdings, Inc. primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and medical devices in the United States and Israel. It operates in three segments, Healthcare, Infusion Technology, and Real Estate. The company engages in the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. Its lead drug candidate is Trappsol Cyclo, which is in phase 3 clinical trial being evaluated for the potential treatment of Niemann-Pick Disease Type C1 ("NPC1"), a rare, fatal and progressive genetic disorder; and CPI-613 (devimistat), a stable analog of normally transient, acylated catalytic intermediates of lipoate, which is in phase II of clinical trial. The company is also involved in developing Promitil, a molecule designed for the targeted delivery of mitomycin-C in a proprietary prodrug form, completed Phase 1A and 1B clinical studies targeting patients with advanced cancers. In addition, it engages in the development of surgical and procedural devices, including orthopedic arthroscopy instrument for Carpal Tunnel syndrome. Rafael Holdings, Inc. was incorporated in 2017 and is headquartered in Newark, New Jersey.
Visit website →Key Statistics
- Market Cap
- $65.74M
- P/E Ratio
- N/A
- 52-Week High
- $3.19
- 52-Week Low
- $1.12
- Avg Volume
- 124.65K
- Beta
- 0.67
Company Info
- Industry
- Real Estate Services
- Exchange
- NYQ
- Country
- United States
- Employees
- 21